title: Pharmacological characterization of postsynaptic alpha-adrenoceptor subtypes in five different dog arteries in-vitro.
abstract: The responses of helically cut strips of arteries isolated from five different sites in the body of dogs to relatively selective alpha 1- and alpha 2-adrenoceptor agonists and the antagonism exerted on these responses by relatively selective alpha 1- and alpha 2-adrenoceptor blockers have been studied. On all arteries (renal, splenic, cranial mesenteric, jejunal and femoral) phenylephrine was a full agonist whereas UK-14,304 was a partial agonist causing maximal contractions of 49, 30, 27, 27 and 10% of the maximum, respectively. Phenylephrine was more potent than UK-14,304, being 9 times more potent in the renal artery and up to 42 times more potent in the cranial mesenteric artery. In the dog saphenous vein, where there are both alpha 1- and alpha 2-adrenoceptors, it has been previously shown that UK-14,304 is 530 times more potent than phenylephrine. Prazosin in low concentrations displaced concentration-response curves for both phenylephrine and UK-14,304 (pA2 values of 8.16-8.43 and 8.13-8.79, respectively) whereas yohimbine was much less potent (pA2 values of 6.53-6.88 and 6.50-7.20, respectively). The results suggest that the alpha-adrenoceptors of all arteries studied are predominantly, if not exclusively, of the alpha 1-subtype.
authors.forename: J J
authors.initials: JJ
authors.lastname: Polónia
authors.forename: M Q
authors.initials: MQ
authors.lastname: Paiva
authors.forename: S
authors.initials: S
authors.lastname: Guimarães
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001158:Arteries / Q000187:drug effects / Q000294:innervation; D000068438:Brimonidine Tartrate; D003042:Cocaine / Q000494:pharmacology; D004285:Dogs; D066298:In Vitro Techniques; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011427:Propiophenones / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D011427:Propiophenones; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D017981:Receptors, Neurotransmitter; D010656:Phenylephrine; D015016:Yohimbine; D000068438:Brimonidine Tartrate; C006104:U 0521; D011433:Propranolol; D003042:Cocaine; D011224:Prazosin